Outside Consultant Will Evaluate FDA's Postmarketing Studies Practices

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 6
Volume 15
Issue 6

The FDA has awarded a $1.09 million contract for an evaluation of the agency's process of establishing postmarketing, or phase IV, studies. The consulting firm of Booz Allen Hamilton will conduct the 1-year evaluation and make recommendations to the agency for improving and standardizing the process.

ROCKVILLE, Maryland—The FDA has awarded a $1.09 million contract for an evaluation of the agency's process of establishing postmarketing, or phase IV, studies. The consulting firm of Booz Allen Hamilton will conduct the 1-year evaluation and make recommendations to the agency for improving and standardizing the process.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts in this video
2 experts in this video
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Related Content